Camurus AB: Camurus Annual Report for 2015 released

LUND, Sweden--()--Regulatory News:

Camurus AB (Nasdaq Stockholm: CAMX) today announces that the Annual Report for 2015 now is available at the company’s website: www.camurus.com

About Camurus

Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company’s share is listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit www.camurus.com

This information was brought to you by Cision http://news.cision.com

Contacts

For more information:
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92 fredrik.tiberg@camurus.com
or
Rein Piir, VP Investor Relations
Tel. +46 (0)70 853 72 92 ir@camurus.com

Contacts

For more information:
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92 fredrik.tiberg@camurus.com
or
Rein Piir, VP Investor Relations
Tel. +46 (0)70 853 72 92 ir@camurus.com